569 related articles for article (PubMed ID: 25294555)
1. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
Blumenfeld A; Gennings C; Cady R
Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/Nap.
Cady R; Nett R; Dexter K; Freitag F; Beach ME; Manley HR
Headache; 2014 Jan; 54(1):80-93. PubMed ID: 24020994
[TBL] [Abstract][Full Text] [Related]
5. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
Headache; 2004; 44(7):661-8. PubMed ID: 15209687
[TBL] [Abstract][Full Text] [Related]
6. Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches.
Gershovich OE; Billups SJ; Delate T; Hoffman CK; Carroll N
J Manag Care Pharm; 2006 Apr; 12(3):246-53. PubMed ID: 16623609
[TBL] [Abstract][Full Text] [Related]
7. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
[TBL] [Abstract][Full Text] [Related]
8. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
9. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine.
Haberer LJ; Walls CM; Lener SE; Taylor DR; McDonald SA
Headache; 2010 Mar; 50(3):357-73. PubMed ID: 20132340
[TBL] [Abstract][Full Text] [Related]
10. SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study.
Cady R; O'Carroll P; Dexter K; Freitag F; Shade CL
Headache; 2014 Jan; 54(1):67-79. PubMed ID: 24021029
[TBL] [Abstract][Full Text] [Related]
11. Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination.
Landy SH; Cady RK; Nelsen A; White J; Runken MC
Headache; 2014 Apr; 54(4):640-54. PubMed ID: 24102322
[TBL] [Abstract][Full Text] [Related]
12. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes.
Cady RK; Diamond ML; Diamond MP; Ballard JE; Lener ME; Dorner DP; Derosier FJ; McDonald SA; White J; Runken MC
Headache; 2011 May; 51(5):664-73. PubMed ID: 21521204
[TBL] [Abstract][Full Text] [Related]
13. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
14. Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescence.
Winner P; Linder S; Hershey AD
Headache; 2015 Apr; 55(4):519-28. PubMed ID: 25881677
[TBL] [Abstract][Full Text] [Related]
15. Effects of switching acute treatment on disability in migraine patients using triptans.
Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
[TBL] [Abstract][Full Text] [Related]
16. A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.
Landy SH; Turner IM; Runken MC; Lee M; Sulcs E; Bell CF
Headache; 2013; 53(7):1134-46. PubMed ID: 23773016
[TBL] [Abstract][Full Text] [Related]
17. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
[No Abstract] [Full Text] [Related]
18. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Brandes JL; Kudrow D; Stark SR; O'Carroll CP; Adelman JU; O'Donnell FJ; Alexander WJ; Spruill SE; Barrett PS; Lener SE
JAMA; 2007 Apr; 297(13):1443-54. PubMed ID: 17405970
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
Berges A; Walls C; Lener SE; McDonald SA
Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
[TBL] [Abstract][Full Text] [Related]
20. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.
Silberstein SD; Feliu AL; Rupnow MF; Blount AC; Boccuzzi SJ
Headache; 2007 Apr; 47(4):500-10. PubMed ID: 17445099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]